92 related articles for article (PubMed ID: 24685884)
1. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Cushen SJ; Power DG; Teo MY; MacEneaney P; Maher MM; McDermott R; O'Sullivan K; Ryan AM
Am J Clin Oncol; 2017 Feb; 40(1):47-52. PubMed ID: 24685884
[TBL] [Abstract][Full Text] [Related]
2. CT-defined sarcopenia predicts treatment response in primary central nervous system lymphomas.
Surov A; Meyer HJ; Hinnerichs M; Ferraro V; Zeremski V; Mougiakakos D; Saalfeld S; Wienke A; Strobel A; Wolleschak D
Eur Radiol; 2024 Feb; 34(2):790-796. PubMed ID: 37178198
[TBL] [Abstract][Full Text] [Related]
3. Can AI-based body composition assessment outperform body surface area in predicting dose-limiting toxicities for colonic cancer patients on chemotherapy?
Cao K; Yeung J; Arafat Y; Choi C; Wei MYK; Chan S; Lee M; Baird PN; Yeung JMC
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13915-13923. PubMed ID: 37540253
[TBL] [Abstract][Full Text] [Related]
4. Body Composition and Anti-Neoplastic Treatment in Adult and Older Subjects - A Systematic Review.
Gérard S; Bréchemier D; Lefort A; Lozano S; Abellan Van Kan G; Filleron T; Mourey L; Bernard-Marty C; Rougé-Bugat ME; Soler V; Vellas B; Cesari M; Rolland Y; Balardy L
J Nutr Health Aging; 2016; 20(8):878-888. PubMed ID: 27709238
[TBL] [Abstract][Full Text] [Related]
5. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact.
Prado CM; Cushen SJ; Orsso CE; Ryan AM
Proc Nutr Soc; 2016 May; 75(2):188-98. PubMed ID: 26743210
[TBL] [Abstract][Full Text] [Related]
6. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
7. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
Daly LE; Power DG; O'Reilly Á; Donnellan P; Cushen SJ; O'Sullivan K; Twomey M; Woodlock DP; Redmond HP; Ryan AM
Br J Cancer; 2017 Jan; 116(3):310-317. PubMed ID: 28072766
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later.
Ryan AM; Power DG; Daly L; Cushen SJ; Ní Bhuachalla Ē; Prado CM
Proc Nutr Soc; 2016 May; 75(2):199-211. PubMed ID: 26786393
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography diagnosed cachexia and sarcopenia in 725 oncology patients: is nutritional screening capturing hidden malnutrition?
Ní Bhuachalla ÉB; Daly LE; Power DG; Cushen SJ; MacEneaney P; Ryan AM
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):295-305. PubMed ID: 29271097
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.
Solheim TS; Laird BJA; Balstad TR; Stene GB; Bye A; Johns N; Pettersen CH; Fallon M; Fayers P; Fearon K; Kaasa S
J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):778-788. PubMed ID: 28614627
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer.
Miyamoto Y; Baba Y; Sakamoto Y; Ohuchi M; Tokunaga R; Kurashige J; Hiyoshi Y; Iwagami S; Yoshida N; Yoshida M; Watanabe M; Baba H
Ann Surg Oncol; 2015 Aug; 22(8):2663-8. PubMed ID: 25564158
[TBL] [Abstract][Full Text] [Related]
13. Muscle wasting in disease: molecular mechanisms and promising therapies.
Cohen S; Nathan JA; Goldberg AL
Nat Rev Drug Discov; 2015 Jan; 14(1):58-74. PubMed ID: 25549588
[TBL] [Abstract][Full Text] [Related]
14. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.
Chen Y; Rini BI; Bair AH; Mugundu GM; Pithavala YK
Clin Pharmacokinet; 2015 Apr; 54(4):397-407. PubMed ID: 25343945
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.
Yamada D; Matsushita H; Azuma T; Nakagawa T; Nagata M; Yamada Y; Suzuki M; Fujimura T; Fukuhara H; Kume H; Homma Y; Kakimi K
Mol Clin Oncol; 2014 Nov; 2(6):1023-1027. PubMed ID: 25279192
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Bellmunt J; Suarez C; Gallardo E; Rodon J; Pons F; Bonfill T; Beltran M; Moya I; Galtes S; Albanell J; Carles J
Oncologist; 2014 Sep; 19(9):917-8. PubMed ID: 25142843
[TBL] [Abstract][Full Text] [Related]
19. Racial disparity in metastatic renal cell cancer: the pharmaco-anthropology of sunitinib.
Zhang A; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):197-9. PubMed ID: 25135199
[No Abstract] [Full Text] [Related]
20. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
Motzer RJ; Barrios CH; Kim TM; Falcon S; Cosgriff T; Harker WG; Srimuninnimit V; Pittman K; Sabbatini R; Rha SY; Flaig TW; Page R; Bavbek S; Beck JT; Patel P; Cheung FY; Yadav S; Schiff EM; Wang X; Niolat J; Sellami D; Anak O; Knox JJ
J Clin Oncol; 2014 Sep; 32(25):2765-72. PubMed ID: 25049330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
